rs1057519864
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Using cell line models of castration-resistant prostate cancer (CRPC), we determined that cellular androgen content influences enzalutamide agonism of mutant F877L AR.
|
27276681 |
2016 |
rs1057519864
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The consequence of suppressing AR-F876L may then abrogate AR-F876L mediated CRPC cell proliferation and metastasis.
|
27233475 |
2016 |
rs1057519864
|
|
|
0.030 |
GeneticVariation |
BEFREE |
AR F876L is sufficient to confer resistance to ARN-509 and enzalutamide in in vitro and in vivo models of castration-resistant prostate cancer (CRPC).
|
23779130 |
2013 |
rs137852578
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Chen and colleagues report that a T878A androgen receptor mutation occurs in a subset of patients progressing while receiving abiraterone, suggesting that this may be a therapeutically exploitable mechanism of abiraterone resistance in castration-resistant prostate cancer.
|
25432158 |
2015 |
rs137852578
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Recently, a novel cyclopeptide <i>Diffusa Cyclotide-3</i> (DC3), isolated from <i>Hedyotisdiffusa</i>, has been experimentally demonstrated to inhibit the survival and growth of LNCap cells, which typically express T877A-mutated AR, the most frequently detected point mutation of AR in castration-resistant prostate cancer (CRPC).
|
29755968 |
2018 |
rs56350726
|
|
|
0.020 |
GeneticVariation |
BEFREE |
And one (SLC28A3, rs56350726) of five SNP was found the association with the progression to CRPC in patients with mPCa.
|
29228579 |
2017 |
rs56350726
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Correction: A genetic variant in SLC28A3, rs56350726, is associated with progression to castration-resistant prostate cancer in a Korean population with metastatic prostate cancer.
|
30159135 |
2018 |
rs1004467
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the logistic regression analysis four genetic polymorphisms, rs743572, rs6162, rs6163, and rs1004467, in the CYP17A1 gene were significantly associated with a risk of progression to CRPC (p < 0.05).
|
22714708 |
2013 |
rs1045642
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Serum LDH may be a promising predictor of prognosis, and the ABCB1 C3435T polymorphism may be a genetic predictor of the severity of leukocytopenia in patients with CRPC treated with DEC.
|
21706123 |
2012 |
rs1047303
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A common 1245 A→C missense-encoding single nucleotide polymorphism in HSD3B1 (rs1047303), the gene that encodes this enzyme, leads to a more stable protein that is resistant to degradation and thus increased production of potent androgens from adrenal precursors, facilitating castration-resistant PCa development.
|
31271415 |
2019 |
rs12422149
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We studied the progression to CRPC for the SLCO1B3 rs4149117 and SLCO2B1 rs12422149 genotypes in 87 prostate cancer patients who received androgen deprivation therapy (ADT).
|
23896625 |
2013 |
rs1395
|
|
|
0.010 |
GeneticVariation |
BEFREE |
No relation to risk was found.Three SNPs were associated with CRPC prognosis in Caucasians: ABCB11 rs7602171G>A (p = 0.003; n = 30; hazard ratio [HR]: 0.307), GSTP1 rs1799811C>T (p = 0.001; n = 38; HR: 0.254) and SLC5A6 rs1395 (p = 0.004; n = 35; HR: 3.15).
|
27883295 |
2016 |
rs1799811
|
|
|
0.010 |
GeneticVariation |
BEFREE |
No relation to risk was found.Three SNPs were associated with CRPC prognosis in Caucasians: ABCB11 rs7602171G>A (p = 0.003; n = 30; hazard ratio [HR]: 0.307), GSTP1 rs1799811C>T (p = 0.001; n = 38; HR: 0.254) and SLC5A6 rs1395 (p = 0.004; n = 35; HR: 3.15).
|
27883295 |
2016 |
rs2149556
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A multivariate model consisting of age, GS, rs2149556 (HR 0.67; 95% CI 0.38-1.18) and rs4372063 (HR 2.17; 95% CI 1.25-3.76) was constructed to predict survival in patients with CRPC (concordance of 0.69, P < 3.2 × 10<sup>-9</sup> ).
|
27410686 |
2017 |
rs2208532
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We studied the polymorphisms rs518673 and rs166050 in SRD5A1, and rs12470143, rs523349, rs676033 and rs2208532 in SRD5A2 as well as the time to CRPC progression and overall survival in 104 patients with metastatic prostate cancer that had undergone primary ADT.
|
26169017 |
2015 |
rs2231142
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The ABCG2 421 C > A (Q141K) polymorphism may be an important predictor of response and survival in HRPC patients treated with docetaxel-based chemotherapy.
|
17062685 |
2006 |
rs2234693
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Patients with CRPC (n=115) treated with docetaxel, single-agent thalidomide (n=42), or healthy controls (n=289) were genotyped for the CYP19 R264C (rs700519) and the ERα PvuII T>C (rs2234693) and XbaI A>G (rs9340799) polymorphisms.
|
21106711 |
2011 |
rs4149117
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We studied the progression to CRPC for the SLCO1B3 rs4149117 and SLCO2B1 rs12422149 genotypes in 87 prostate cancer patients who received androgen deprivation therapy (ADT).
|
23896625 |
2013 |
rs4372063
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A multivariate model consisting of age, GS, rs2149556 (HR 0.67; 95% CI 0.38-1.18) and rs4372063 (HR 2.17; 95% CI 1.25-3.76) was constructed to predict survival in patients with CRPC (concordance of 0.69, P < 3.2 × 10<sup>-9</sup> ).
|
27410686 |
2017 |
rs5472
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for peptide vaccine efficacy in castration-resistant prostate cancer patients.
|
26428930 |
2015 |
rs564250
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In metastatic prostate cancer, the AG/GG allele in GSTM3 rs7483 and CT/TT allele in CAT rs564250 were associated with a significantly lower risk of progression to CRPC and all-cause death compared with homozygotes of the major AA allele (hazard ratio [HR]; [95% confidence interval (CI)], 0.55 [0.34-0.86], P = 0.0086) and CC allele (HR; [95% CI], 0.48 [0.24-0.88], P = 0.016), respectively.
|
27993795 |
2017 |
rs6162
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the logistic regression analysis four genetic polymorphisms, rs743572, rs6162, rs6163, and rs1004467, in the CYP17A1 gene were significantly associated with a risk of progression to CRPC (p < 0.05).
|
22714708 |
2013 |
rs6163
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the logistic regression analysis four genetic polymorphisms, rs743572, rs6162, rs6163, and rs1004467, in the CYP17A1 gene were significantly associated with a risk of progression to CRPC (p < 0.05).
|
22714708 |
2013 |
rs676033
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We studied the polymorphisms rs518673 and rs166050 in SRD5A1, and rs12470143, rs523349, rs676033 and rs2208532 in SRD5A2 as well as the time to CRPC progression and overall survival in 104 patients with metastatic prostate cancer that had undergone primary ADT.
|
26169017 |
2015 |
rs700519
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Patients with CRPC (n=115) treated with docetaxel, single-agent thalidomide (n=42), or healthy controls (n=289) were genotyped for the CYP19 R264C (rs700519) and the ERα PvuII T>C (rs2234693) and XbaI A>G (rs9340799) polymorphisms.
|
21106711 |
2011 |